Global ADHD Therapeutics Market Growth 2018-2023
Published On: October 2018
 
Report ID:351832
 
 
Pages: 160




Attention Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder with an estimated global prevalence of 5.3% in children and adolescents. Diagnosis most commonly occurs in children, but the importance of identifying ADHD in the adult population has risen in the past decade. However, diagnosis remains difficult due to unknown genetic causes and a lack of accurate biomarkers.

Over the next five years, LPI(LP Information) projects that ADHD Therapeutics will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global ADHD Therapeutics market for 2018-2023.

This report presents a comprehensive overview, market shares, and growth opportunities of ADHD Therapeutics market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

Stimulants

Non-stimulants

Segmentation by application:

Specialty Clinics

Hospital Pharmacies

Retail Pharmacies

E-Commerce

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Spain

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

Eli Lilly

Novartis

Shire

Pfizer

GlaxoSmithKline

Mallinckrodt Pharmaceuticals

Hisamitsu Pharmaceutical

Impax Laboratories

Johnson & Johnson

UCB S.A.

Purdue Parma

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

To study and analyze the global ADHD Therapeutics consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.

To understand the structure of ADHD Therapeutics market by identifying its various subsegments.

Focuses on the key global ADHD Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the ADHD Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of ADHD Therapeutics submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Contents

2018-2023 Global ADHD Therapeutics Consumption Market Report

1 Scope of the Report

1.1 Market Introduction

1.2 Research Objectives

1.3 Years Considered

1.4 Market Research Methodology

1.5 Economic Indicators

1.6 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global ADHD Therapeutics Consumption 2013-2023

2.1.2 ADHD Therapeutics Consumption CAGR by Region

2.2 ADHD Therapeutics Segment by Type

2.2.1 Stimulants

2.2.2 Non-stimulants

2.3 ADHD Therapeutics Consumption by Type

2.3.1 Global ADHD Therapeutics Consumption Market Share by Type (2013-2018)

2.3.2 Global ADHD Therapeutics Revenue and Market Share by Type (2013-2018)

2.3.3 Global ADHD Therapeutics Sale Price by Type (2013-2018)

2.4 ADHD Therapeutics Segment by Application

2.4.1 Specialty Clinics

2.4.2 Hospital Pharmacies

2.4.3 Retail Pharmacies

2.4.4 E-Commerce

2.5 ADHD Therapeutics Consumption by Application

2.5.1 Global ADHD Therapeutics Consumption Market Share by Application (2013-2018)

2.5.2 Global ADHD Therapeutics Value and Market Share by Application (2013-2018)

2.5.3 Global ADHD Therapeutics Sale Price by Application (2013-2018)

3 Global ADHD Therapeutics by Players

3.1 Global ADHD Therapeutics Sales Market Share by Players

3.1.1 Global ADHD Therapeutics Sales by Players (2016-2018)

3.1.2 Global ADHD Therapeutics Sales Market Share by Players (2016-2018)

3.2 Global ADHD Therapeutics Revenue Market Share by Players

3.2.1 Global ADHD Therapeutics Revenue by Players (2016-2018)

3.2.2 Global ADHD Therapeutics Revenue Market Share by Players (2016-2018)

3.3 Global ADHD Therapeutics Sale Price by Players

3.4 Global ADHD Therapeutics Manufacturing Base Distribution, Sales Area, Product Types by Players

3.4.1 Global ADHD Therapeutics Manufacturing Base Distribution and Sales Area by Players

3.4.2 Players ADHD Therapeutics Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 ADHD Therapeutics by Regions

4.1 ADHD Therapeutics by Regions

4.1.1 Global ADHD Therapeutics Consumption by Regions

4.1.2 Global ADHD Therapeutics Value by Regions

4.2 Americas ADHD Therapeutics Consumption Growth

4.3 APAC ADHD Therapeutics Consumption Growth

4.4 Europe ADHD Therapeutics Consumption Growth

4.5 Middle East & Africa ADHD Therapeutics Consumption Growth

5 Americas

5.1 Americas ADHD Therapeutics Consumption by Countries

5.1.1 Americas ADHD Therapeutics Consumption by Countries (2013-2018)

5.1.2 Americas ADHD Therapeutics Value by Countries (2013-2018)

5.2 Americas ADHD Therapeutics Consumption by Type

5.3 Americas ADHD Therapeutics Consumption by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC ADHD Therapeutics Consumption by Countries

6.1.1 APAC ADHD Therapeutics Consumption by Countries (2013-2018)

6.1.2 APAC ADHD Therapeutics Value by Countries (2013-2018)

6.2 APAC ADHD Therapeutics Consumption by Type

6.3 APAC ADHD Therapeutics Consumption by Application

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 Key Economic Indicators of Few APAC Countries

7 Europe

7.1 Europe ADHD Therapeutics by Countries

7.1.1 Europe ADHD Therapeutics Consumption by Countries (2013-2018)

7.1.2 Europe ADHD Therapeutics Value by Countries (2013-2018)

7.2 Europe ADHD Therapeutics Consumption by Type

7.3 Europe ADHD Therapeutics Consumption by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

7.9 Spain

7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

8.1 Middle East & Africa ADHD Therapeutics by Countries

8.1.1 Middle East & Africa ADHD Therapeutics Consumption by Countries (2013-2018)

8.1.2 Middle East & Africa ADHD Therapeutics Value by Countries (2013-2018)

8.2 Middle East & Africa ADHD Therapeutics Consumption by Type

8.3 Middle East & Africa ADHD Therapeutics Consumption by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact

9.1.1 Growing Demand from Key Regions

9.1.2 Growing Demand from Key Applications and Potential Industries

9.2 Market Challenges and Impact

9.3 Market Trends

10 Marketing, Distributors and Customer

10.1 Sales Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.2 ADHD Therapeutics Distributors

10.3 ADHD Therapeutics Customer

11 Global ADHD Therapeutics Market Forecast

11.1 Global ADHD Therapeutics Consumption Forecast (2018-2023)

11.2 Global ADHD Therapeutics Forecast by Regions

11.2.1 Global ADHD Therapeutics Forecast by Regions (2018-2023)

11.2.2 Global ADHD Therapeutics Value Forecast by Regions (2018-2023)

11.2.3 Americas Consumption Forecast

11.2.4 APAC Consumption Forecast

11.2.5 Europe Consumption Forecast

11.2.6 Middle East & Africa Consumption Forecast

11.3 Americas Forecast by Countries

11.3.1 United States Market Forecast

11.3.2 Canada Market Forecast

11.3.3 Mexico Market Forecast

11.3.4 Brazil Market Forecast

11.4 APAC Forecast by Countries

11.4.1 China Market Forecast

11.4.2 Japan Market Forecast

11.4.3 Korea Market Forecast

11.4.4 Southeast Asia Market Forecast

11.4.5 India Market Forecast

11.4.6 Australia Market Forecast

11.5 Europe Forecast by Countries

11.5.1 Germany Market Forecast

11.5.2 France Market Forecast

11.5.3 UK Market Forecast

11.5.4 Italy Market Forecast

11.5.5 Russia Market Forecast

11.5.6 Spain Market Forecast

11.6 Middle East & Africa Forecast by Countries

11.6.1 Egypt Market Forecast

11.6.2 South Africa Market Forecast

11.6.3 Israel Market Forecast

11.6.4 Turkey Market Forecast

11.6.5 GCC Countries Market Forecast

11.7 Global ADHD Therapeutics Forecast by Type

11.8 Global ADHD Therapeutics Forecast by Application

12 Key Players Analysis

12.1 Eli Lilly

12.1.1 Company Details

12.1.2 ADHD Therapeutics Product Offered

12.1.3 Eli Lilly ADHD Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)

12.1.4 Main Business Overview

12.1.5 Eli Lilly News

12.2 Novartis

12.2.1 Company Details

12.2.2 ADHD Therapeutics Product Offered

12.2.3 Novartis ADHD Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)

12.2.4 Main Business Overview

12.2.5 Novartis News

12.3 Shire

12.3.1 Company Details

12.3.2 ADHD Therapeutics Product Offered

12.3.3 Shire ADHD Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)

12.3.4 Main Business Overview

12.3.5 Shire News

12.4 Pfizer

12.4.1 Company Details

12.4.2 ADHD Therapeutics Product Offered

12.4.3 Pfizer ADHD Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)

12.4.4 Main Business Overview

12.4.5 Pfizer News

12.5 GlaxoSmithKline

12.5.1 Company Details

12.5.2 ADHD Therapeutics Product Offered

12.5.3 GlaxoSmithKline ADHD Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)

12.5.4 Main Business Overview

12.5.5 GlaxoSmithKline News

12.6 Mallinckrodt Pharmaceuticals

12.6.1 Company Details

12.6.2 ADHD Therapeutics Product Offered

12.6.3 Mallinckrodt Pharmaceuticals ADHD Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)

12.6.4 Main Business Overview

12.6.5 Mallinckrodt Pharmaceuticals News

12.7 Hisamitsu Pharmaceutical

12.7.1 Company Details

12.7.2 ADHD Therapeutics Product Offered

12.7.3 Hisamitsu Pharmaceutical ADHD Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)

12.7.4 Main Business Overview

12.7.5 Hisamitsu Pharmaceutical News

12.8 Impax Laboratories

12.8.1 Company Details

12.8.2 ADHD Therapeutics Product Offered

12.8.3 Impax Laboratories ADHD Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)

12.8.4 Main Business Overview

12.8.5 Impax Laboratories News

12.9 Johnson & Johnson

12.9.1 Company Details

12.9.2 ADHD Therapeutics Product Offered

12.9.3 Johnson & Johnson ADHD Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)

12.9.4 Main Business Overview

12.9.5 Johnson & Johnson News

12.10 UCB S.A.

12.10.1 Company Details

12.10.2 ADHD Therapeutics Product Offered

12.10.3 UCB S.A. ADHD Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)

12.10.4 Main Business Overview

12.10.5 UCB S.A. News

12.11 Purdue Parma

13 Research Findings and Conclusion




Please fill the form below, to recieve the report sample

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*

Please fill the form below for enquiry

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*
   Our Clients
  • \
   Payment Mode



For More Information

   For More Information

If you have any query? Please contact us

sales@fiormarkets.com
+1-201-465-4211


Copyright © 2019 Fior Market Research LLP, All Rights Reserved.